$0.2814
0.001900.68%
At close: -
$0.2894
0.008002.84%
After Hours: 7:44 PM EDT
Comments
Loading...
IGC Pharma Earnings Estimates, EPS & Revenue | AMEX:IGC | Benzinga
IGC Pharma reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Jun 23
EPS Estimate
$-0.030
Quarterly Revenue Estimate
$295.00K
Annual Revenue
(as of Dec 31)
(as of Dec 31)
$1.24M
Analyze the earnings history of IGC Pharma using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IGC | IGC Pharma | -$0.04 | -$0.03 | — | — | $295.00K | $295.00K | — | — | 06/23/2025 | Get Alert |
| IGC | IGC Pharma | -$0.09 | -$0.03 | -$0.02 | 33.33% | $204.00K | $204.00K | $257.00K | 25.98% | 02/18/2025 | Get Alert |
| IGC | IGC Pharma | -$0.05 | -$0.03 | -$0.02 | 33.33% | $291.00K | $300.00K | $412.00K | 37.33% | 11/12/2024 | Get Alert |
| IGC | IGC Pharma | -$0.04 | -$0.04 | -$0.03 | 25.00% | $555.00K | $620.00K | $272.00K | -56.13% | 08/08/2024 | Get Alert |
| IGC | IGC Pharma | -$0.08 | -$0.04 | -$0.04 | 0.00% | $166.00K | $190.00K | $295.00K | 55.26% | 06/24/2024 | Get Alert |
| IGC | IGC Pharma | -$0.04 | — | -$0.09 | — | $332.00K | — | $204.00K | — | 02/14/2024 | Get Alert |
| IGC | IGC Pharma | -$0.05 | — | -$0.05 | — | $202.00K | — | $291.00K | — | 11/13/2023 | Get Alert |
| IGC | IGC Pharma | -$0.05 | — | -$0.04 | — | $212.00K | — | $555.00K | — | 08/10/2023 | Get Alert |
| IGC | IGC Pharma | -$0.12 | — | -$0.08 | — | $122.00K | — | $166.00K | — | 07/07/2023 | Get Alert |
| IGC | IGC Pharma | -$0.05 | — | -$0.04 | — | $142.00K | — | $332.00K | — | 02/14/2023 | Get Alert |
| IGC | IGC Pharma | -$0.09 | — | -$0.05 | — | $56.00K | — | $202.00K | — | 11/01/2022 | Get Alert |
| IGC | IGC Pharma | -$0.04 | — | -$0.05 | — | $77.00K | — | $212.00K | — | 08/08/2022 | Get Alert |
| IGC | IGC Pharma | -$0.07 | — | -$0.12 | — | $81.00K | — | $122.00K | — | 06/22/2022 | Get Alert |
| IGC | IGC Pharma | -$0.06 | — | -$0.05 | — | $108.00K | — | $142.00K | — | 02/10/2022 | Get Alert |
| IGC | IGC Pharma | $0.04 | — | -$0.09 | — | $125.00K | — | $56.00K | — | 10/29/2021 | Get Alert |
| IGC | IGC Pharma | -$0.05 | — | -$0.04 | — | $584.00K | — | $77.00K | — | 08/11/2021 | Get Alert |
| IGC | IGC Pharma | -$0.08 | — | -$0.07 | — | $29.00K | — | $81.00K | — | 06/14/2021 | Get Alert |
| IGC | IGC Pharma | -$0.04 | — | -$0.06 | — | $573.00K | — | $108.00K | — | 02/13/2021 | Get Alert |
| IGC | IGC Pharma | -$0.03 | — | $0.04 | — | $1.82M | — | $125.00K | — | 11/22/2020 | Get Alert |
| IGC | IGC Pharma | -$0.03 | — | -$0.05 | — | $1.65M | — | $584.00K | — | 08/19/2020 | Get Alert |
| IGC | IGC Pharma | -$0.06 | — | -$0.08 | — | $1.54M | — | $29.00K | — | 07/13/2020 | Get Alert |
IGC Pharma (IGC) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | 2025-02-18 | $-0.02 | $-0.03 | 33.3 % |
| Q2 | 2024-11-12 | $-0.02 | $-0.03 | 33.3 % |
| Q1 | 2024-08-08 | $-0.03 | $-0.04 | 25.0 % |
| Q4 | 2024-06-24 | $-0.04 | $-0.04 | 0.00 % |
IGC Pharma (IGC) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | 2025-02-18 | $257.00K | $204.00K | 26.0 % |
| Q2 | 2024-11-12 | $412.00K | $300.00K | 37.3 % |
| Q1 | 2024-08-08 | $272.00K | $620.00K | -56.1 % |
| Q4 | 2024-06-24 | $295.00K | $190.00K | 55.3 % |
FAQ
When is IGC Pharma (AMEX:IGC) reporting earnings?
IGC Pharma (IGC) is scheduled to report earnings on June 23, 2025. The last reported earnings were for reported on February 18, 2025 for Q3.
What were the latest earnings per share (EPS) for IGC Pharma (AMEX:IGC)?
The Actual EPS was $-0.02, which beat the estimate of $-0.03.
What were IGC Pharma’s (AMEX:IGC) revenues?
The Actual Revenue was $257K, which beat the estimate of $204K.
Browse earnings estimates, EPS, and revenue on all stocks.